Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]

Suleiman Massarweh; Edward Romond; Esther P. Black; Emily Van Meter; Brent Shelton; Vera Kadamyan-Melkumian; Mark Stevens; Richard Elledge

doi:10.1007/s10549-015-3263-0

Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]

Suleiman Massarweh, Edward Romond, Esther P. Black, Emily Van Meter, Brent Shelton, Vera Kadamyan-Melkumian, Mark Stevens, Richard Elledge

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	565
Number of pages	1
Journal	Breast Cancer Research and Treatment
Volume	149
Issue number	2
DOIs	https://doi.org/10.1007/s10549-015-3263-0
State	Published - Jan 2015

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-015-3263-0

Fingerprint

Dive into the research topics of 'Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]'. Together they form a unique fingerprint.

Cite this

Massarweh, S., Romond, E., Black, E. P., Van Meter, E., Shelton, B., Kadamyan-Melkumian, V., Stevens, M., & Elledge, R. (2015). Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]. Breast Cancer Research and Treatment, 149(2), 565. https://doi.org/10.1007/s10549-015-3263-0

Massarweh, Suleiman ; Romond, Edward ; Black, Esther P. et al. / Erratum to : A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]. In: Breast Cancer Research and Treatment. 2015 ; Vol. 149, No. 2. pp. 565.

@article{c5040ee4ade3473d9b44a712db384109,

title = "Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]",

author = "Suleiman Massarweh and Edward Romond and Black, {Esther P.} and {Van Meter}, Emily and Brent Shelton and Vera Kadamyan-Melkumian and Mark Stevens and Richard Elledge",

year = "2015",

month = jan,

doi = "10.1007/s10549-015-3263-0",

language = "English",

volume = "149",

pages = "565",

number = "2",

}

Massarweh, S, Romond, E, Black, EP, Van Meter, E, Shelton, B, Kadamyan-Melkumian, V, Stevens, M & Elledge, R 2015, 'Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]', Breast Cancer Research and Treatment, vol. 149, no. 2, pp. 565. https://doi.org/10.1007/s10549-015-3263-0

Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]. / Massarweh, Suleiman; Romond, Edward; Black, Esther P. et al.
In: Breast Cancer Research and Treatment, Vol. 149, No. 2, 01.2015, p. 565.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to

T2 - A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]

AU - Massarweh, Suleiman

AU - Romond, Edward

AU - Black, Esther P.

AU - Van Meter, Emily

AU - Shelton, Brent

AU - Kadamyan-Melkumian, Vera

AU - Stevens, Mark

AU - Elledge, Richard

PY - 2015/1

Y1 - 2015/1

UR - http://www.scopus.com/inward/record.url?scp=84921929197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921929197&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3263-0

DO - 10.1007/s10549-015-3263-0

M3 - Comment/debate

AN - SCOPUS:84921929197

SN - 0167-6806

VL - 149

SP - 565

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V et al. Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]. Breast Cancer Research and Treatment. 2015 Jan;149(2):565. doi: 10.1007/s10549-015-3263-0

Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this